Skip to content
Screener

Royalty Pharma RPRX Q1 2026 earnings

Reported May 6, 2026 · Before market open

Revenue$925.0MBeat by $43.3M
EPS$1.30Beat by $0.08
Revenue estimate$881.7M
EPS estimate$1.22

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$877.4M
EPS estimate$1.16

Financials

Q1 2026

Income statement

See full
Revenue$630.6M+11.0%
Operating income$563.0M+5.4%
Net income$294.7M+23.1%
EPS (diluted)$0.67+21.8%

Balance sheet

See full
Cash & equivalents$586.4M-46.1%
Total debt$9.0B+17.8%
Total equity$9.9B+1.6%
Total assets$19.8B+12.5%

Cash flow

See full
Operating cash flow$718.2M+20.5%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$20.55B+52.4%
Enterprise value$28.94B+44.6%
P/E24.8×+12.4×
P/S8.4×+2.5×

Profitability

See full
Operating margin65.1%-18.9pp
Net margin34%-14.3pp

Returns & leverage

See full
Return on equity8.4%-2.7pp
Debt / equity0.9×+0.1×
Current ratio2.7×+1.1×

FAQ

When did Royalty Pharma report Q1 2026 earnings?
Royalty Pharma (RPRX) reported Q1 2026 earnings on May 6, 2026 before market open.
What were Royalty Pharma's Q1 2026 revenue and EPS?
Royalty Pharma reported revenue of $925.0M and eps of $1.30 for Q1 2026.
Did Royalty Pharma beat estimates in Q1 2026?
Revenue beat the consensus estimate of $881.7M by $43.3M. EPS beat the consensus estimate of $1.22 by $0.08.
How did Royalty Pharma's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 62.8% from $568.2M a year earlier and eps grew 22.6% from $1.06.
Where can I find Royalty Pharma's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001802768-26-000008) and the 10-Q periodic report (0001802768-26-000009) directly on SEC EDGAR. The filing index links above go to sec.gov.